Is Zepbound Approved for Obesity?
Yes, Zepbound (tirzepatide) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with weight-related conditions like high blood pressure, type 2 diabetes, or high cholesterol. Approval came in November 2023 for patients with BMI ≥30 or BMI ≥27 with comorbidities.[1]
How Does Zepbound Differ from Mounjaro?
Zepbound and Mounjaro both contain tirzepatide but target different uses. Mounjaro is approved for type 2 diabetes; Zepbound is for obesity. The dosing is identical, but labeling and marketing differ to comply with FDA rules on off-label promotion.[1]
Who Qualifies for Zepbound Treatment?
Eligible adults include those with:
- BMI ≥30 kg/m² (obesity), or
- BMI ≥27 kg/m² plus at least one weight-related issue (e.g., cardiovascular disease, dyslipidemia, or sleep apnea).
It's used with diet and exercise, not as a standalone fix. Not approved for cosmetic weight loss or under-18s.[1]
What Clinical Trial Data Supports Its Use in Obesity?
SURMOUNT trials showed 15-21% average weight loss over 72 weeks at highest doses (15 mg weekly), versus 3% on placebo. About 30% of patients lost ≥20% body weight. Heart safety was confirmed in SELECT trial data (for semaglutide-related context, but tirzepatide showed similar benefits).[1][2]
Common Side Effects and Patient Concerns
Most report nausea, diarrhea, vomiting, constipation, or stomach pain—often mild and decreasing over time. Serious risks include thyroid tumors (boxed warning), pancreatitis, gallbladder issues, and low blood sugar if combined with insulin. Kidney problems or severe allergic reactions are rarer. Patients often ask about "Ozempic face" (facial sagging from rapid loss), manageable with slower titration.[1]
How Does Zepbound Compare to Wegovy or Saxenda?
Zepbound leads in weight loss head-to-head data: up to 21% vs. Wegovy's (semaglutide) 15%. Dual GLP-1/GIP action gives it an edge over GLP-1-only drugs like Wegovy or Saxenda (liraglutide). Cost is similar (~$1,000/month without insurance); coverage varies by obesity diagnosis.[2]
Cost, Access, and Insurance Coverage
List price is $1,059/month. Manufacturer savings cards cut it to $25 for eligible insured patients (up to 13 fills). Medicare covers for obesity with comorbidities since 2024; private insurance often requires prior authorization and documentation of lifestyle attempts.[1]
Patent Status and Generic/Biosimilar Timeline
Eli Lilly holds patents on tirzepatide until at least 2036, with formulation patents to 2039. No generics expected soon; challenges from competitors like Viking Therapeutics are ongoing but distant. Check DrugPatentWatch.com for expiry details and litigation updates.[3]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
[2] NEJM SURMOUNT-1: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[3] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/ZEPBOUND